---
figid: PMC3069769__JCI44145.f1
figtitle: 'Next-generation mTOR inhibitors in clinical oncology: how pathway complexity
  informs therapeutic strategy'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3069769
filename: JCI44145.f1.jpg
figlink: /pmc/articles/PMC3069769/figure/F1/
number: F1
caption: 'mTOR-based targeting strategies are presented in the context of the PI3K/mTOR
  signaling network. Pathways activating mTOR via RTKs and PI3K are shown together
  with effectors regulating protein and lipid biosynthesis and cell cycle. mTORC1
  and mTORC2 modulate cell cycle via effects on Cdk inhibitors p21 and p27, cyclin
  D1, and cyclin E; SREBPs and ACL regulate lipid biosynthesis downstream of AKT;
  mTORC1 phosphorylates 4EBP1 and S6K1 to activate critical drivers of global protein
  translation. Also represented are important feedback pathways whereby mTORC1 reduces
  signaling through PI3K and mTORC2: S6K1 phosphorylates IRS1, promoting its proteolysis;
  S6K1 phosphorylates Rictor to inhibit mTORC2-dependent AKT activation. The TSC1/2
  complex serves as a relay center for tumor microenvironmental queues. Oncogenic
  PI3K/PDK1 and Ras/MAPK signaling cooperate to reduce TSC1/2 activity. Hypoxia (via
  HIF1α), DNA damage (via p53), and nutrient deprivation (via LKB1) all activate TSC1/2
  to restrain mTORC1 and biosynthetic processes in normal tissue. These pathways are
  often inactivated during tumorigenesis. Rapalogs are mTORC1-specific inhibitors.
  TOR-KIs more potently inhibit both mTOR complexes. Dual PI3K/TOR-KIs additionally
  block upstream signaling via PI3K. Green circles represent stimulatory phosphorylations;
  red circles, inhibitory phosphorylations.'
papertitle: 'Next-generation mTOR inhibitors in clinical oncology: how pathway complexity
  informs therapeutic strategy.'
reftext: Seth A. Wander, et al. J Clin Invest. 2011 Apr 1;121(4):1231-1241.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9535932
figid_alias: PMC3069769__F1
figtype: Figure
redirect_from: /figures/PMC3069769__F1
ndex: 0fdf1703-deef-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3069769__JCI44145.f1.html
  '@type': Dataset
  description: 'mTOR-based targeting strategies are presented in the context of the
    PI3K/mTOR signaling network. Pathways activating mTOR via RTKs and PI3K are shown
    together with effectors regulating protein and lipid biosynthesis and cell cycle.
    mTORC1 and mTORC2 modulate cell cycle via effects on Cdk inhibitors p21 and p27,
    cyclin D1, and cyclin E; SREBPs and ACL regulate lipid biosynthesis downstream
    of AKT; mTORC1 phosphorylates 4EBP1 and S6K1 to activate critical drivers of global
    protein translation. Also represented are important feedback pathways whereby
    mTORC1 reduces signaling through PI3K and mTORC2: S6K1 phosphorylates IRS1, promoting
    its proteolysis; S6K1 phosphorylates Rictor to inhibit mTORC2-dependent AKT activation.
    The TSC1/2 complex serves as a relay center for tumor microenvironmental queues.
    Oncogenic PI3K/PDK1 and Ras/MAPK signaling cooperate to reduce TSC1/2 activity.
    Hypoxia (via HIF1α), DNA damage (via p53), and nutrient deprivation (via LKB1)
    all activate TSC1/2 to restrain mTORC1 and biosynthetic processes in normal tissue.
    These pathways are often inactivated during tumorigenesis. Rapalogs are mTORC1-specific
    inhibitors. TOR-KIs more potently inhibit both mTOR complexes. Dual PI3K/TOR-KIs
    additionally block upstream signaling via PI3K. Green circles represent stimulatory
    phosphorylations; red circles, inhibitory phosphorylations.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tie
  - Ras85D
  - InR
  - Pdk1
  - Mtor
  - Tor
  - Sin1
  - rictor
  - Pten
  - DCTN6-p27
  - dap
  - CG9588
  - ras
  - Ras64B
  - CycE
  - cyc
  - Ask1
  - Akt
  - gig
  - p53
  - betaTub60D
  - hth
  - Tsc1
  - SNF4Agamma
  - AMPKalpha
  - ATPCL
  - Lkb1
  - Rheb
  - raptor
  - PRAS40
  - Crtc
  - Thor
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - PDK1
  - PDPK1
  - SGK1
  - IRS1
  - DEPTOR
  - PTEN
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - MAP3K5
  - AKT1
  - AKT2
  - AKT3
  - CCNE1
  - CCNE2
  - DDIT4
  - TSC2
  - TP53
  - TP63
  - TP73
  - TSC1
  - CCL26
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ACLY
  - STK11
  - RHEB
  - RHEBP1
  - AKT1S1
  - RPTOR
  - EIF4EBP1
  - EIF4E
  - EIF4E2
  - EIF4E3
  - STK25
  - Cancer
  - Lung cancer
---
